JL18008

Phase 1Small molecule

JJecho Biopharmaceuticals Co., Ltd.

JL18008 is one of 4 small molecule programs targeting Interleukin. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InterleukinNot yet recruiting

InterleukinPhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Interleukin

#DrugCompanyPhaseTrials

Actemra

CCelltrion

Phase 2

4 2

N-803

IImmunityBio, Inc.

Phase 2

1 3

Crixivan

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 4

JL18008

JJecho Biopharmaceuticals Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1Not yet recruiting

Interleukin

NCT07443228

Clinical

Trials by Indication[1]

Interleukin1 trial

Recombinant Human Interleukin-7 (JL18008) for the Treatment of HIV-Infected Immunological Non-Responders

Not yet recruiting·JJecho Biopharmaceuticals Co., Ltd.·Phase 1·NCT07443228·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JL18008. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JL18008 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JL18008. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jecho Biopharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJecho Biopharmaceuticals Co., Ltd.

JL18008

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Interleukin1 trial

References

Drug Info

Quick Facts

Related News